NASDAQ:GALT

Galectin Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy GALT

*Your capital is at risk

$2.97

-0.260 (-8.05%)

At Close: Jul 31, 2026

Galectin Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -48.56. In total, the insiders bought 2.42M and sold 495.22K GALT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-48.56
● Buy	2.42M shares
● Sell	495.22K shares
73% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Jun 29, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -48.56. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 02, 2026 Sell	Common Stock S-Sale	Jamil Khurram Chief Medical Officer	Officer	13 055 Value: $54.8K
Jan 02, 2026 Sell	Common Stock S-Sale	Lewis Joel President And CEO	CEO / President	18 571 Value: $77.9K
Jan 02, 2026 Buy	Common Stock M-Exempt	Lewis Joel President And CEO	CEO / President	84 000 Value: $340.2K
Jan 02, 2026 Buy	Common Stock M-Exempt	Jamil Khurram Chief Medical Officer	Officer	60 000 Value: $243.0K
Jan 02, 2026 Sell	Common Stock S-Sale	Callicutt Jack W Chief Financial Officer	C-Suite Officer	13 914 Value: $58.4K
Jan 02, 2026 Buy	Common Stock M-Exempt	Callicutt Jack W Chief Financial Officer	C-Suite Officer	60 000 Value: $243.0K
Jan 02, 2026 Buy	Restricted Stock Unit M-Exempt	Lewis Joel President And CEO	CEO / President	84 000 Value: $340.2K
Jan 01, 2026 Buy	Restricted Stock Unit M-Exempt	Jamil Khurram Chief Medical Officer	Officer	60 000 Value: $178.2K
Jan 01, 2026 Buy	Restricted Stock Unit M-Exempt	Callicutt Jack W Chief Financial Officer	C-Suite Officer	60 000 Value: $178.2K
Dec 31, 2025 Buy	Stock option (right to buy) M-Exempt	Jamil Khurram Chief Medical Officer	Officer	8 125 Value: $10K
Dec 31, 2025 Sell	Common Stock S-Sale	Jamil Khurram Chief Medical Officer	Officer	8 125 Value: $33.1K
Dec 31, 2025 Buy	Common Stock M-Exempt	Jamil Khurram Chief Medical Officer	Officer	8 125 Value: $10K
Dec 23, 2025 Buy	Common Stock P-Purchase	Freeman Kevin D Director	Director	5 500 Value: $19.5K
Dec 23, 2025 Buy	Common Stock P-Purchase	Eldred Kary Director	Director	700 Value: $3K
Dec 17, 2025 Sell	Common Stock S-Sale	Lewis Joel President And CEO	CEO / President	7 829 Value: $55.2K
Dec 17, 2025 Buy	Stock option (right to buy) M-Exempt	Lewis Joel President And CEO	CEO / President	7 829 Value: $22.4K
Dec 17, 2025 Buy	Stock option (right to buy) M-Exempt	Jamil Khurram Chief Medical Officer	Officer	6 463 Value: $14.2K
Dec 17, 2025 Buy	Stock option (right to buy) M-Exempt	Jamil Khurram Chief Medical Officer	Officer	8 500 Value: $21.3K
Dec 17, 2025 Buy	Common Stock M-Exempt	Jamil Khurram Chief Medical Officer	Officer	8 500 Value: $21.3K
Dec 17, 2025 Buy	Common Stock M-Exempt	Jamil Khurram Chief Medical Officer	Officer	6 463 Value: $14.2K
Dec 17, 2025 Sell	Common Stock S-Sale	Jamil Khurram Chief Medical Officer	Officer	8 500 Value: $59.8K
Dec 17, 2025 Buy	Common Stock M-Exempt	Shlevin Harold H. Director	Director	20 000 Value: $39.6K
Dec 17, 2025 Sell	Common Stock S-Sale	Shlevin Harold H. Director	Director	19 793 Value: $139.3K
Dec 17, 2025 Sell	Common Stock S-Sale	Shlevin Harold H. Director	Director	4 706 Value: $33.1K
Dec 17, 2025 Buy	Stock Option (right to buy) M-Exempt	Shlevin Harold H. Director	Director	20 000 Value: $39.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALECTIN THERAPEUTICS INC.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti...

Read Full Profile Here